Delivered-To: tjphuhs@gmail.com Received: by 2002:adf:f549:0:b0:441:282b:bd with SMTP id j9csp83309wrp; Wed, 29 Apr 2026 04:04:28 -0700 (PDT) X-Received: by 2002:a05:622a:40ca:b0:50f:c8f9:d5d9 with SMTP id d75a77b69052e-5100e1bef8cmr91168041cf.39.1777460668519; Wed, 29 Apr 2026 04:04:28 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1777460668; cv=none; d=google.com; s=arc-20240605; b=htJqts91WprfckH/2WdB3JtsfYPEiTyqTZjCPOBKxvoZTERlRiodL0u/RYlOhT9lVw INsJ2nOeOEdhv7D4K9LBk6hCdY0wcm1WNo/VHzXVCVrn8hg7olLZPi14O9lDzIn1piv9 Wjj0I4tOxQu3EgsJD+R3hHQd049WMnBXEOYaBu2M2P3nwt5dil3b9P65XK0OB1zPBpVa BjvtLuIMYFMoTzqbZxxkQPLNE5vUP2934qw+7E+1AAh2Hjg3dwdMwNd53OEIJ6YWR++I rvGNL6Z9ahmq1Gzhr1nK8btMTQlvGuZDUUBCuhgfaffue2jzMDFI7Q7aIZB7u1Bec0Kq CYpw== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=message-id:list-unsubscribe:o:feedback-id:list-unsubscribe-post:to :from:subject:mime-version:date:sender:dkim-signature:dkim-signature :dkim-signature; bh=eJt25tbyyRNKyiEK1IRBl3/4nm1KY8UBaMFBUlKMtZ0=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=JWKDmkCrbB++ZLL7e05ZpT935e9DqYFTmoOVSlnc3MfmLGVHfKUU2Ih+9Uj7uTqQwJ yrBcSKqnEk53LL+gXVz4C/mfKy4rDmVY07SxI5foFUsvcMfXoNtBIt5s5sX3eKR6qebE bSWLhLFBbxKY/j7fLs+hL6BRAMzrYDAl7RKzyj2dVYZ0vsJetqqJsISoI1yHiNSGxKV1 KYbRHhCpL7LpdPrv5ssr8n79F12K/QZW56GzI5qPlMLsKn8NdzAWs0YqZKgo5jrqgAIf YzrqxHBks7F46XA2kdgdg5sdyosWvdNgMKb9pwkblnXga5Msdc1j6Qnz25z9Fyzx2PKB GrVg==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@dkim1.omnisend.email header.s=omni2 header.b=6Ua0xpGw; dkim=pass header.i=@simplepeptide.com header.s=mx header.b=tz6x1Jfx; dkim=pass header.i=@mailgun.org header.s=mg header.b=T5hqDFa8; spf=pass (google.com: domain of bounce+b00d8c.1e320f9-tjphuhs=gmail.com@simplepeptide.com designates 204.220.169.131 as permitted sender) smtp.mailfrom="bounce+b00d8c.1e320f9-tjphuhs=gmail.com@simplepeptide.com"; dmarc=pass (p=QUARANTINE sp=QUARANTINE dis=NONE) header.from=simplepeptide.com Return-Path: Received: from g131.gb126d70.use4.send.mailgun.net (g131.gb126d70.use4.send.mailgun.net. [204.220.169.131]) by mx.google.com with UTF8SMTPS id 6a1803df08f44-8b3ef9a87fdsi18576666d6.342.2026.04.29.04.04.28 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Wed, 29 Apr 2026 04:04:28 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+b00d8c.1e320f9-tjphuhs=gmail.com@simplepeptide.com designates 204.220.169.131 as permitted sender) client-ip=204.220.169.131; Authentication-Results: mx.google.com; dkim=pass header.i=@dkim1.omnisend.email header.s=omni2 header.b=6Ua0xpGw; dkim=pass header.i=@simplepeptide.com header.s=mx header.b=tz6x1Jfx; dkim=pass header.i=@mailgun.org header.s=mg header.b=T5hqDFa8; spf=pass (google.com: domain of bounce+b00d8c.1e320f9-tjphuhs=gmail.com@simplepeptide.com designates 204.220.169.131 as permitted sender) smtp.mailfrom="bounce+b00d8c.1e320f9-tjphuhs=gmail.com@simplepeptide.com"; dmarc=pass (p=QUARANTINE sp=QUARANTINE dis=NONE) header.from=simplepeptide.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=dkim1.omnisend.email; q=dns/txt; s=omni2; t=1777460667; x=1777467867; h=Message-Id: List-Unsubscribe: List-Unsubscribe-Post: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: Date: Sender: Sender: X-Feedback-Id; bh=eJt25tbyyRNKyiEK1IRBl3/4nm1KY8UBaMFBUlKMtZ0=; b=6Ua0xpGwnEc7fagSFTfUWwTlLWjugqrOr+hlvPKZTIr2tjTNluayVizBpv49Xx6OSk6Bk6d4z5sCihKYCMF2zsA5/2GemkpyDgMbcXv0o6f7RiyOLown1N4G2cRD4UrUlRe/mmrsirCW7/AvsIcu5fL5fFGicXpdzA/oncFEtrss4lisrip24C9T2jScU8OG73W1T0qGFuDKAiCw+P8DLu1kXRSyQLB6joVBltA0ehxTWBJrdP3350lCNJ8x7d83Tr3lS3UWCs8wweK3727fWaYxqZaVJ5h2UGJ/ycwNXzX0nzkbjGQxSmRH6JjSE7w+YJkA0heobQkzqJSRRwnwJg== DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=simplepeptide.com; q=dns/txt; s=mx; t=1777460667; x=1777467867; h=Message-Id: List-Unsubscribe: List-Unsubscribe-Post: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: Date: Sender: Sender: X-Feedback-Id; bh=eJt25tbyyRNKyiEK1IRBl3/4nm1KY8UBaMFBUlKMtZ0=; b=tz6x1JfxXuzne1FoGWWylMa2XJHWfAcvNHbSDV/twTbasIaccrloUCwxS0r/pta6Aczp64+MBY7UcMggvBQSOPtyTXs26u6UidD1X4hNO7YBe4rBIBQ3ZZq4guJkCvIvhWR/hqQwRo8Cv/BmEfgcnhEtpKZrWeuBau13VYVXhpA= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1777460667; x=1777467867; h=Message-Id: List-Unsubscribe: List-Unsubscribe-Post: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: Date: Sender: Sender: X-Feedback-Id; bh=eJt25tbyyRNKyiEK1IRBl3/4nm1KY8UBaMFBUlKMtZ0=; b=T5hqDFa8NTt4rD2W8sGLYdxyYYx685OVqbURhmL/bnL10zxmu0sb0wraVjVjIhnO2eUpYBT1OAR4BYzheXWI5FhvSpzy4dNeVpJXQFX/jyikm10uRH390wVspP6Nxdj2h3s2DHY7gjazVTAP8dI+ugvjwC0MWF8Vt5fjB6LYkzs= X-Mailgun-Sid: WyJiMTY3ZiIsInRqcGh1aHNAZ21haWwuY29tIiwiMWUzMjBmOSJd X-Feedback-Id: support@simplepeptide.com::6842137ba5beeb5ef138be2e:mailgun Received: by 127e50a10252bf7347ab8cfb4c25f7bf449758d2aa3ad5931f0d2f2da3a4ca94 with HTTP id 69f1e5bb14ea299efe99e933; Wed, 29 Apr 2026 11:04:25 GMT X-Mailgun-Sending-Ip-Pool-Name: BstS X-Mailgun-Sending-Ip-Pool: 665596289f43bfa346f3584f X-Mailgun-Sending-Ip: 204.220.169.131 X-Mailgun-Batch-Id: 69f1e5b94b78b926f7c0b85c Sender: support@simplepeptide.com Date: Wed, 29 Apr 2026 11:04:25 +0000 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="5ab7fab59f723be9fe8f1b80cec71ceb92bbada88b3f76e6e382241ecb6d" Subject: =?UTF-8?b?8J+aqCBCQUNLIElOIFNUT0NLIPCfmqg=?= From: Simple Peptide To: tjphuhs@gmail.com X-Mailgun-Secondary-Dkim: dkim1.omnisend.email,omni2 X-Mailgun-Track: false List-Unsubscribe-Post: List-Unsubscribe=One-Click Feedback-Id: 69ef8d76757957a8268f871a:68405b213a5771675694ea59:campaign:omnisend O:secondary-Dkim: dkim1.omnisend.email,omni2 List-Unsubscribe: X-Mailgun-Variables: {"brandID": "68405b213a5771675694ea59", "contactID": "6864b11c9f318c74accf8c6b", "progressID": "69f0cc5e653e73f440c8e840"} Message-Id: <20260429110425.e486227037c59407@simplepeptide.com> --5ab7fab59f723be9fe8f1b80cec71ceb92bbada88b3f76e6e382241ecb6d Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable SLU-PP-332 1MG Capsules Available Now This email was sent to you as HTML-only. To view it, please visit:=20 https://ptv.soundestlink.com/ce/v/6864b11c9f318c74accf8c6b/69f0cc5e653e73f4= 40c8e840 ************************** Make sure you keep getting our latest offers and add support@simplepeptide.= com to your address book. Unsubscribe=20 https://ptv.soundestlink.com/contactsPreferences/v2/unsubscribe/?b=3D68405b= 213a5771675694ea59&c=3D6864b11c9f318c74accf8c6b&payload=3DAVQ2vUeU9YGtGoskI= vmpbQ8McN3VeudqZY9yAkcog8v2e2ta-Z6FVvxSs8zL4nuMKT8yKVWc061FGW-cGJArQQFDARUF= KKiRkYPTlaTjnGB1NeRBDwcYPdrS93iBRExHBhhv Visit site https://simplepeptide.com =C2=96 --5ab7fab59f723be9fe8f1b80cec71ceb92bbada88b3f76e6e382241ecb6d Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable =F0=9F=9A=A8 BACK IN STOCK =F0=9F=9A=A8

= SLU-PP-332 1MG Capsules Available Now

͏ ͏ ͏ ͏ ͏ ͏ &= #847; ͏ ͏ ͏ ͏ ͏ T= 7; ͏ ͏ ͏ ͏ ͏ ͏&= nbsp;͏ ͏ ͏ ͏ ͏ ͏&nbs= p;͏ ͏ ͏ ͏ ͏ ͏ &= #847; ͏ ͏ ͏ ͏ ͏ T= 7; ͏ ͏ ͏ ͏ ͏ ͏&= nbsp;͏ ͏ ͏ ͏ ͏ ͏&nbs= p;͏ ͏ ͏ ͏ ͏ ͏ &= #847; ͏ ͏ ͏ ͏ ͏ T= 7; ͏ ͏ ͏ ͏ ͏ ͏&= nbsp;͏ ͏ ͏ ͏ ͏ ͏&nbs= p;͏ ͏ ͏ ͏ ͏ ͏ &= #847; ͏ ͏ ͏ ͏ ͏ T= 7; ͏ ͏ ͏ ͏ ͏ ͏&= nbsp;͏ ͏ ͏ ͏ ͏ ͏&nbs= p;͏ ͏ ͏ ͏ ͏ ͏ &= #847; ͏ ͏ ͏ ͏ ͏ T= 7; ͏ ͏ ͏ ͏ ͏ ͏&= nbsp;͏ ͏ ͏ ͏ ͏ ͏&nbs= p;͏ ͏ ͏ ͏ ͏ ͏ &= #847; ͏ ͏ ͏ ͏ ͏ T= 7; ͏ ͏ ͏ ͏ ͏ ͏&= nbsp;͏ ͏ ͏ ͏ ͏ ͏&nbs= p; ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ &sh= y; ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ = ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ &sh= y; ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ = ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ &sh= y; ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ = ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ &sh= y; ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ = ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ &sh= y; ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ = ­ ­ ­ ­ ­

= 3D""
=
3D""
3D""

SLU-PP-332 CAPSULES 1MG

BACK IN STOCK


SLU-PP-332 is being studied for how it influences cellular e= nergy regulation.


Interest in this compound is tied to its inte= raction with pathways typically activated during sustained physical output,= particularly those related to mitochondrial activity and metabolic efficie= ncy.


Its relevance comes from how it signals, not how = it stimulates.

=
 

WHAT IT IS 

SLU-PP-332 is a small-molecule compound studied for how it = activates estrogen-related receptors (ERRs), particularly ERR=CE=B1.


These rec= eptors help regulate how cells produce and use energy.

<= td style=3D"font-size:0;line-height:0;border-top:1px dashed #FFFFFF;"> 

WHAT IT DOES 

(IN RESEARCH)


Activation of= ERR=CE=B1 shifts how energy is produced and used at the cellular level.

=E2=96=B8 Higher energy expenditure signaling &nb= sp;


=E2=96=B8 Greater reliance on fat as fuel 


 =E2=96=B8 Activation of endurance-related pathway= s 

=
 

FORMAT 


=E2=96=B8 1mg per capsule  


=E2=96=B8 Pre-measured for consistency 


 =E2=96=B8 Capsule delivery for standardized use  

3D""
<= td style=3D"font-size:0;line-height:0;border-top:1px dashed #FFFFFF;"> 

WHY STUDY 1MG?


=E2=96=B8 Defined, repeatable exposure 

=E2=96=B8 Clearer observation of metabolic respons= e

<= td style=3D"font-size:0;line-height:0;border-top:1px dashed #FFFFFF;"> 

SLU-PP-332 continues to be studied within the context of meta= bolic signaling and cellular energy regulation. Ongoing interest reflects = the importance of these pathways in research settings.

=
 
3D"3=

Select SP compounds are now available at 20%off.

Explore current inventory while = promotional pricing remains active.
=
 

Follow us for= news, updates and special upcoming promotions!

3D"facebook" 3D"instagram"

Edit preferences or Unsubscribe

--5ab7fab59f723be9fe8f1b80cec71ceb92bbada88b3f76e6e382241ecb6d--